# US 8,278,066 B2 · Truncated somatostatin receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,066 B2
- Document ID: US8278066B2
- Status: Granted
- Kind: B2
- Application number: 13/226,289
- Filed: 2011-09-06
- Published: 2012-05-03
- Granted: 2012-10-02
- Earliest claimed: 2001-02-15
- Assignees: Board of Regents, The University of Texas System
- Inventors: Vikas Kundra
- Web page: https://patentgrep.com/patent/US8278066B2

## CPC

- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- C07K 2319/02: containing a signal sequence
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fusion tag. Alternatively, a fusion protein may be fused to a leader sequence. A leader sequence may localize an expressed protein, e.g. localize a fusion protein to the cell membrane. The invention includes nucleic acids encoding the fusion proteins and methods of assaying for gene expression.

## Claims

### Claim 1

A mutant human somatostatin type 2 receptor polypeptide in which the portion of the cytoplasmic tail C-terminal to amino acid 314 has been deleted.

### Claim 2 (depends on 1)

The polypeptide of claim 1, fused to a second polypeptide to form a fusion protein.

### Claim 3 (depends on 2)

The fusion protein of claim 2, wherein said second polypeptide comprises a tag.

### Claim 4 (depends on 2)

The fusion protein of claim 2, wherein said second polypeptide comprises a leader sequence.

### Claim 5 (depends on 4)

The fusion protein of claim 4, wherein said leader sequence is the Igκ leader sequence.

### Claim 6 (depends on 1)

An isolated nucleic acid encoding the polypeptide of claim 1.

### Claim 7 (depends on 6)

An expression vector comprising the nucleic acid of claim 6, operably linked to a promoter.

### Claim 8 (depends on 7)

A host cell transformed with the vector of claim 7.

### Claim 9 (depends on 7)

A method of expressing a polypeptide comprising:
a) transferring a gene into a host cell with an expression vector according to claim 7; and
b) permitting the cell to express said polypeptide.

### Claim 10 (depends on 9)

The method of claim 9, wherein the gene transfer takes place in vivo.

### Claim 11 (depends on 9)

The method of claim 9, further comprising assaying said expression by contacting said host cell with a ligand that binds with specificity to a somatostatin receptor, or mutated somatostatin receptor, and wherein said ligand has been detectably labeled.

### Claim 12 (depends on 11)

The method of claim 11, wherein the expression of said vector is assayed by contacting said host cell with a ligand that binds with specificity to a somatostatin type 2 receptor, or mutated somatostatin type 2 receptor, and wherein said ligand has been detectably labeled.

### Claim 13 (depends on 11)

The method of claim 11, wherein said ligand is radioactively labeled somatostatin analog.

### Claim 14 (depends on 11)

The method of claim 11, wherein said ligand is radioactively labeled octreotide.

### Claim 15 (depends on 9)

The method of claim 9, wherein the expression of said vector is assayed by contacting said host cell with an antibody that binds with specificity to said polypeptide.
